The preliminary results from 25 patients with NSCLC containing EGFR exon 20 insertion mutations revealed that 10 patients (40%) exhibited a partial response (PR), 14 (56%) had stable disease (SD), and 1 (4%) had progressive disease (PD) as their best response. This evidence concerns the gene EGFR and non-small cell lung carcinoma.